Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized

(American College of Cardiology) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news